Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
IUBMB Life ; 72(6): 1243-1249, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32356940

RESUMO

A pool of Plasmodium falciparum casein kinase 1 (PfCK1) has been shown to localize to the host red blood cell (RBC) membrane and be secreted to the extracellular medium during trophozoite stage of development. We attempted to identify mechanisms for secretion of PfCK1 and its appearance on the RBC membrane. We found that two host proteins with established functions in membrane trafficking in higher eukaryotes, GTPase-activating protein and Vps9 domain-containing protein 1 (GAPVD1), and Sorting nexin 22, consistently co-purify with PfCK1, suggesting that the parasite utilizes trafficking pathways previously thought to be inactive in RBCs. Furthermore, reciprocal immunoprecipitation experiments with GAPVD1 identified parasite proteins suggestive of a protein recycling pathway hitherto only described in higher eukaryotes. Thus, we have identified components of a trafficking pathway involving parasite proteins that act in concert with host proteins, and which we hypothesize mediates trafficking of PfCK1 to the RBC during infection.


Assuntos
Caseína Quinase I/metabolismo , Interações Hospedeiro-Patógeno/fisiologia , Plasmodium falciparum/patogenicidade , Proteínas de Protozoários/metabolismo , Caseína Quinase I/genética , Membrana Celular/metabolismo , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Humanos , Malária Falciparum/metabolismo , Malária Falciparum/parasitologia , Espectrometria de Massas , Plasmodium falciparum/genética , Plasmodium falciparum/metabolismo , Transporte Proteico , Proteínas de Protozoários/genética , Nexinas de Classificação/metabolismo
2.
Nature ; 465(7296): 305-10, 2010 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-20485427

RESUMO

Malaria is a devastating infection caused by protozoa of the genus Plasmodium. Drug resistance is widespread, no new chemical class of antimalarials has been introduced into clinical practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs. We screened nearly 2 million compounds in GlaxoSmithKline's chemical library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2 microM concentration. More than 8,000 also showed potent activity against the multidrug resistant strain Dd2. Most (82%) compounds originate from internal company projects and are new to the malaria community. Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets. Chemical structures and associated data are hereby made public to encourage additional drug lead identification efforts and further research into this disease.


Assuntos
Antimaláricos/análise , Antimaláricos/farmacologia , Descoberta de Drogas , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/análise , Bibliotecas de Moléculas Pequenas/farmacologia , Animais , Antimaláricos/química , Antimaláricos/toxicidade , Linhagem Celular Tumoral , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Humanos , Malária Falciparum/parasitologia , Modelos Biológicos , Filogenia , Plasmodium falciparum/enzimologia , Plasmodium falciparum/genética , Plasmodium falciparum/crescimento & desenvolvimento , Bibliotecas de Moléculas Pequenas/química , Bibliotecas de Moléculas Pequenas/toxicidade
3.
Antimicrob Agents Chemother ; 55(12): 5740-5, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21968362

RESUMO

Malaria is one of the deadliest infectious diseases in the world, with the eukaryotic parasite Plasmodium falciparum causing the most severe form of the disease. Discovery of new classes of antimalarial drugs has become an urgent task to counteract the increasing problem of drug resistance. Screening directly for compounds able to inhibit parasite growth in vitro is one of the main approaches the malaria research community is now pursuing for the identification of novel antimalarial drug leads. Very recently, thousands of compounds with potent activity against the parasite P. falciparum have been identified and information about their molecular descriptors, antiplasmodial potency, and cytotoxicity is publicly available. Now the challenges are how to identify the most promising chemotypes for further development and how best to progress these compounds through a lead optimization program to generate antimalarial drug candidates. We report here the first chemical series to be characterized from one of those screenings, a completely novel chemical class with the generic name cyclopropyl carboxamides that has never before been described as having antimalarial or other pharmacological activities. Cyclopropyl carboxamides are potent inhibitors of drug-sensitive and -resistant strains of P. falciparum in vitro and show in vivo oral efficacy in malaria mouse models. In the present work, we describe the biological characterization of this chemical family, showing that inhibition of their still unknown target has very favorable pharmacological consequences but the compounds themselves seem to select for resistance at a high frequency.


Assuntos
Amidas , Antimaláricos , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Amidas/química , Amidas/farmacologia , Amidas/uso terapêutico , Amidas/toxicidade , Animais , Antimaláricos/química , Antimaláricos/farmacologia , Antimaláricos/uso terapêutico , Antimaláricos/toxicidade , Linhagem Celular , Eritrócitos/parasitologia , Feminino , Humanos , Malária Falciparum/parasitologia , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Testes de Sensibilidade Parasitária , Plasmodium falciparum/crescimento & desenvolvimento , Relação Estrutura-Atividade , Resultado do Tratamento
4.
Commun Biol ; 3(1): 701, 2020 11 20.
Artigo em Inglês | MEDLINE | ID: mdl-33219324

RESUMO

Mitosis has been validated by numerous anti-cancer drugs as being a druggable process, and selective inhibition of parasite proliferation provides an obvious opportunity for therapeutic intervention against malaria. Mitosis is controlled through the interplay between several protein kinases and phosphatases. We show here that inhibitors of human mitotic kinases belonging to the Aurora family inhibit P. falciparum proliferation in vitro with various potencies, and that a genetic selection for mutant parasites resistant to one of the drugs, Hesperadin, identifies a resistance mechanism mediated by a member of a different kinase family, PfNek1 (PF3D7_1228300). Intriguingly, loss of PfNek1 catalytic activity provides protection against drug action. This points to an undescribed functional interaction between Ark and Nek kinases and shows that existing inhibitors can be used to validate additional essential and druggable kinase functions in the parasite.


Assuntos
Aurora Quinases , Epistasia Genética , Indóis/farmacologia , Quinase 1 Relacionada a NIMA , Plasmodium falciparum , Sulfonamidas/farmacologia , Aurora Quinases/antagonistas & inibidores , Aurora Quinases/química , Aurora Quinases/metabolismo , Epistasia Genética/efeitos dos fármacos , Epistasia Genética/genética , Humanos , Quinase 1 Relacionada a NIMA/química , Quinase 1 Relacionada a NIMA/genética , Quinase 1 Relacionada a NIMA/metabolismo , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/crescimento & desenvolvimento , Plasmodium falciparum/metabolismo , Proteínas de Protozoários/antagonistas & inibidores , Proteínas de Protozoários/química , Proteínas de Protozoários/metabolismo
5.
Parasit Vectors ; 12(1): 306, 2019 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-31208455

RESUMO

Here, the scientific and patent literature on the activities of purified natural compounds has been reviewed, with the aim of assessing their suitability as anthelmintic drug discovery starting points. Only compounds described as active against parasitic nematodes of animals or against the model nematode Caenorhabditis elegans have been analysed. Scientific articles published since 2010 and patents granted from 2000, both inclusive, have been included in this analysis. The results show a scarcity of novel chemical structures, a limited follow-up of compounds disclosed before 2010 and a bias towards the screening of plant products, almost to the exclusion of other sources, when microbial extracts have, historically, provided most starting points for anti-infective drugs. All plant products published in this period were previously known, alerting to the high re-discovery rates of a limited number of chemical classes from this source. The most promising compounds described in the literature reviewed here, namely the linear nemadectin-derivatives, are novel and of bacterial origin. Patented but otherwise unpublished spiroketal structures also appear as interesting scaffolds for future development. The patent literature confirmed that it is possible to patent derivatives of previously known products, making them valid starting points for translational research.


Assuntos
Anti-Helmínticos/farmacologia , Produtos Biológicos/química , Produtos Biológicos/farmacologia , Nematoides/efeitos dos fármacos , Extratos Vegetais/farmacologia , Animais , Anti-Helmínticos/química , Bactérias/química , Descoberta de Drogas , Humanos , Patentes como Assunto , Extratos Vegetais/química
6.
Artigo em Inglês | MEDLINE | ID: mdl-30690282

RESUMO

In the present study, the anthelmintic activity of a human tyrosine kinase inhibitor, AG-1295, and 14 related tetrahydroquinoxaline analogues against Haemonchus contortus was explored. These compounds were screened against parasitic larvae - exsheathed third-stage (xL3) and fourth-stage (L4) - using a whole-organism screening assay. All compounds were shown to have inhibitory effects on larval motility, development and growth, and induced evisceration through the excretory pore in xL3s. The estimated IC50 values ranged from 3.5 to 52.0 µM for inhibition of larval motility or development. Cytotoxicity IC50 against human MCF10A cells was generally higher than 50 µM. Microscopic studies revealed that this eviscerated (Evi) phenotype occurs rapidly (<20 min) and relates to a protrusion of internal tissues and organs (evisceration) through the excretory pore in xL3s; severe pathological damage in L4s as well as a suppression of larval growth in both stages were also observed. Using a relatively low concentration (12.5 µM) of compound m10, it was established that the inhibitor has to be present for a relatively short time (between 30 h and 42 h) during in vitro development from xL3 to L4, to induce the Evi phenotype. Increasing external osmotic pressure prevented evisceration and moulting, and xL3s remained unaffected by the test compound. These results point to a mode of action involving a dysregulation of morphogenetic processes during a critical time-frame, in agreement with the expected behaviour of a tyrosine kinase inhibitor, and suggest potential for development of this compound class as nematocidal drugs.


Assuntos
Antinematódeos/farmacologia , Haemonchus/efeitos dos fármacos , Quinoxalinas/farmacologia , Tirfostinas/farmacologia , Animais , Bioensaio , Descoberta de Drogas , Haemonchus/fisiologia , Concentração Inibidora 50 , Larva/efeitos dos fármacos , Larva/fisiologia , Muda/efeitos dos fármacos , Fenótipo
8.
Int J Parasitol Drugs Drug Resist ; 8(2): 295-303, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29775797

RESUMO

Phenotypic screening has produced most of the new chemical entities currently in clinical development for malaria, plus many lead compounds active against Plasmodium falciparum asexual stages. However, lack of knowledge about the mode of action of these compounds delays and may even hamper their future development. Identifying the mode of action of the inhibitors greatly helps to prioritise compounds for further development as novel antimalarials. Here we describe a whole-cell method to detect inhibitors of the mitochondrial electron transport chain, using oxygen consumption as high throughput readout in 384-well plate format. The usefulness of the method has been confirmed with the Tres Cantos Antimalarial Compound Set (TCAMS). The assay identified 124 respiratory inhibitors in TCAMS, seven of which were novel anti-plasmodial chemical structures never before described as mitochondrial inhibitors.


Assuntos
Antimaláricos/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Mitocôndrias/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Descoberta de Drogas/métodos , Avaliação Pré-Clínica de Medicamentos/instrumentação , Complexo de Proteínas da Cadeia de Transporte de Elétrons/antagonistas & inibidores , Humanos , Concentração Inibidora 50 , Malária/tratamento farmacológico , Malária/parasitologia , Malária Falciparum , Oxigênio/metabolismo , Plasmodium falciparum/citologia
9.
Trends Parasitol ; 33(11): 831-832, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28923378

RESUMO

A study recently published in Nature links reduced calorie nutritional intake of host mice with (i) reduced severity of cerebral malaria, (ii) decreased parasitemia, and (iii) activation of a nutrient-sensing pathway that regulates the parasite's proliferation rate. Here, we discuss these findings in the context of human malaria pathology and Plasmodium kinomics.


Assuntos
Restrição Calórica , Interações Hospedeiro-Parasita , Malária/parasitologia , Plasmodium/enzimologia , Animais , Humanos , Inflamação , Malária/patologia , Fosfotransferases/genética , Fosfotransferases/metabolismo , Plasmodium/genética , Plasmodium/metabolismo , Proteínas de Protozoários/genética , Proteínas de Protozoários/metabolismo
10.
Curr Pharm Des ; 19(2): 270-81, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-22973885

RESUMO

The malaria parasite has been allowed to get perilously close to winning the upper hand in the race between new drugs and resistance development. Today, just one class of drugs is left to avoid a public health disaster of global proportions, the artemisinins, and even they are showing signs of a possible impending failure. Rational approaches to overcoming antimalarial drug resistance are difficult for several reasons. Resistance mechanisms are varied and imperfectly known across Plasmodium species and often there is not a good correlation between in vitro drug susceptibility, molecular markers of resistance and therapeutic failure, except for antimalarials acting on well defined molecular targets such as atovaquone and the antifolates. Drugs with more complex modes of action are expected to have correspondingly complex resistance mechanisms. Molecular markers of resistance for the most widely used quinoline, chloroquine, have been identified, but they are not applicable to all parasite species and perhaps not even to all strains. Analyses of drug resistance in vitro are also limited by the fact that only one malaria parasite species, Plasmodium falciparum, is amenable to long term culture. Nevertheless, reducing the risk of premature therapeutic failure due to quick resistance emergence needs to be considered from the earliest stages of drug discovery. In the present review we attempt to summarize the main mechanisms of resistance to current antimalarials and provide information on already available assays to estimate the propensity of a new molecule to select for resistant parasites.


Assuntos
Antimaláricos/farmacologia , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Animais , Desenho de Fármacos , Descoberta de Drogas , Resistência a Medicamentos , Humanos , Malária Falciparum/parasitologia , Terapia de Alvo Molecular , Plasmodium falciparum/isolamento & purificação
11.
Chem Biol ; 19(1): 116-29, 2012 Jan 27.
Artigo em Inglês | MEDLINE | ID: mdl-22284359

RESUMO

Malaria, a devastating infectious disease caused by Plasmodium spp., leads to roughly 655,000 deaths per year, mostly of African children. To compound the problem, drug resistance has emerged to all classical antimalarials and may be emerging for artemisinin-based combination therapies. To address the need for new antimalarials with novel mechanisms, several groups carried out phenotypic screening campaigns to identify compounds inhibiting growth of the blood stages of Plasmodium falciparum. In this review, we describe the characterization of these compounds, explore currently ongoing strategies to develop lead molecules, and endorse the concept of a "malaria box" of publicly accessible active compounds.


Assuntos
Antimaláricos/química , Malária/prevenção & controle , Antimaláricos/farmacologia , Antimaláricos/uso terapêutico , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Resistência a Medicamentos , Humanos , Malária/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos
12.
PLoS One ; 7(2): e30949, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22383983

RESUMO

Chemotherapy is still the cornerstone for malaria control. Developing drugs against Plasmodium parasites and monitoring their efficacy requires methods to accurately determine the parasite killing rate in response to treatment. Commonly used techniques essentially measure metabolic activity as a proxy for parasite viability. However, these approaches are susceptible to artefacts, as viability and metabolism are two parameters that are coupled during the parasite life cycle but can be differentially affected in response to drug actions. Moreover, traditional techniques do not allow to measure the speed-of-action of compounds on parasite viability, which is an essential efficacy determinant. We present here a comprehensive methodology to measure in vitro the direct effect of antimalarial compounds over the parasite viability, which is based on limiting serial dilution of treated parasites and re-growth monitoring. This methodology allows to precisely determine the killing rate of antimalarial compounds, which can be quantified by the parasite reduction ratio and parasite clearance time, which are key mode-of-action parameters. Importantly, we demonstrate that this technique readily permits to determine compound killing activities that might be otherwise missed by traditional, metabolism-based techniques. The analysis of a large set of antimalarial drugs reveals that this viability-based assay allows to discriminate compounds based on their antimalarial mode-of-action. This approach has been adapted to perform medium throughput screening, facilitating the identification of fast-acting antimalarial compounds, which are crucially needed for the control and possibly the eradication of malaria.


Assuntos
Antimaláricos/farmacologia , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Plasmodium falciparum/metabolismo , Animais , Técnicas de Cultura de Células/métodos , Avaliação Pré-Clínica de Medicamentos , Humanos , Hipoxantina/química , Concentração Inibidora 50 , Reprodutibilidade dos Testes , Fatores de Tempo , Resultado do Tratamento
13.
Chem Biol ; 18(12): 1602-10, 2011 Dec 23.
Artigo em Inglês | MEDLINE | ID: mdl-22195562

RESUMO

Here we report the discovery of tetracyclic benzothiazepines (BTZs) as highly potent and selective antimalarials along with the identification of the Plasmodium falciparum cytochrome bc(1) complex as the primary functional target of this novel compound class. Investigation of the structure activity relationship within this previously unexplored chemical scaffold has yielded inhibitors with low nanomolar activity. A combined approach employing genetically modified parasites, biochemical profiling, and resistance selection validated inhibition of cytochrome bc(1) activity, an essential component of the parasite respiratory chain and target of the widely used antimalarial drug atovaquone, as the mode of action of this novel compound class. Resistance to atovaquone is eroding the efficacy of this widely used antimalarial drug. Intriguingly, BTZ-based inhibitors retain activity against atovaquone resistant parasites, suggesting this chemical class may provide an alternative to atovaquone in combination therapy.


Assuntos
Antimaláricos/química , Complexo III da Cadeia de Transporte de Elétrons/antagonistas & inibidores , Plasmodium falciparum/efeitos dos fármacos , Tiazepinas/química , Animais , Antimaláricos/síntese química , Antimaláricos/farmacologia , Atovaquona/química , Atovaquona/farmacologia , Sítios de Ligação , Complexo III da Cadeia de Transporte de Elétrons/genética , Complexo III da Cadeia de Transporte de Elétrons/metabolismo , Camundongos , Dados de Sequência Molecular , Mutação , Testes de Sensibilidade Parasitária , Plasmodium falciparum/enzimologia , Estrutura Terciária de Proteína , Reprodutibilidade dos Testes , Relação Estrutura-Atividade , Tiazepinas/síntese química , Tiazepinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA